Errata Corrige

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg
Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
Department of Hematology, Institut Catalá d’Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona
Maria Sklodowska–Curie National Research Institute of Oncology, Kraków
Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni
Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA
1st Department of Internal Medicine, Semmelweis University, Budapest
Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara
Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona
Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool
Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir
Department of Medicine III, LMU University Hospital, Munich
Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne
Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont-Ferrand
Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg
Institute of Pathology, University of Würzburg, Würzburg
MorphoSys AG, Planegg
MorphoSys AG, Planegg
MorphoSys AG, Planegg
Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon
Haematologica Early view Aug 19, 2021 https://doi.org/10.3324/haematol.2021.279802